FrancophonIA/ELRC3.0 huggingface dataset:
English: ↔ Buprenorphine AUC 0.98 (0.81, 1.19) Cmax 0.90 (0.76, 1.07)
Lithuanian: ↔ buprenorfino AUC 0,98 (0,81; 1,19) Cmax 0,90 (0,76; 1,07)
English: GT 1, 4, 6 TN with or without cirrhosis Opiate agonist therapy
Lithuanian: GT 1, 4, 6 TN su ciroze arba be jos, vartoję opiatų agonistų
English: Sustained virologic response (SVR) was the primary endpoint in all studies and was defined as HCV RNA less than the lower limit of quantification (LLOQ: 15 HCV RNA IU/mL except in C-WORTHY and C-SCAPE [25 HCV RNA IU/mL]) at 12 weeks after the cessation of treatment (SVR12).
Lithuanian: 15 TV/ml HCV RNR, išskyrus C-WORTHY ir C-SCAPE tyrimus, kurių metu ji buvo 25 TV/mL HCV RNR (praėjus 12 savaičių po gydymo, SVA12).
English: • EBR* + GZR* for 12 weeks (N=122)
Lithuanian: • EBR* + GZR* 12 savaičių (N=122)
English: ↔ Elvitegravir AUC 1.10 (1.00, 1.21) Cmax 1.02 (0.93, 1.11) C24 1.31 (1.11, 1.55)
Lithuanian: ↔ elvitegraviro AUC 1,10 (1,00; 1,21) Cmax 1,02 (0,93; 1,11) C24 1,31 (1,11; 1,55)
English: Among genotype 1b-infected subjects, NS3 resistance-associated substitutions persisted at detectable levels at follow-up week 24 in 50% (1/2) of subjects.
Lithuanian: Ištyrus 1b genotipo virusais infekuotus žmones, po 24 savaičių nustatomas kiekis su atsparumu susijusių NS3 pakeitimų rastas 50 % (1 iš 2).
English: In genotype 4 replicons, single NS5A substitutions L30S, M31V, and Y93H reduced elbasvir antiviral activity by 3to 23-fold.
Lithuanian: 4 genotipo replikonuose vienas NS5A pakeitimas L30S, M31V ar Y93H sumažindavo elbasviro priešvirusinį aktyvumą nuo 3 iki 23 kartų.
English: ↔ Grazoprevir AUC 1.26 (0.97, 1.64) Cmax 1.26 (0.83, 1.90) C24 1.11 (1.00, 1.23)
Lithuanian: ↔ grazopreviro AUC 1,26 (0,97; 1,64) Cmax 1,26 (0,83; 1,90) C24 1,11 (1,00; 1,23)
English: ↑ Rosuvastatin AUC 1.59 (1.33, 1.89) Cmax 4.25 (3.25, 5.56) C24 0.80 (0.70, 0.91)
Lithuanian: ↑ rozuvastatino AUC 1,59 (1,33; 1,89) Cmax 4,25 (3,25; 5,56) C24 0,80 (0,70; 0,91) (žarnų BCRP slopinimas)
English: ↔ Elbasvir AUC 1.98 (1.84, 2.13) Cmax 1.95 (1.84, 2.07) C24 2.21 (1.98, 2.47)
Lithuanian: ↔ elbasviro AUC 1,98 (1,84; 2,13) Cmax 1,95 (1,84; 2,07) C24 2,21 (1,98; 2,47)
English: Calcium acetate (2,668 mg single dose)/ elbasvir (50 mg single dose)/ grazoprevir (100 mg single dose)
Lithuanian: Kalcio acetatas (2668 mg vienkartinė dozė) / elbasviras (50 mg vienkartinė dozė) / grazopreviras (100 mg vienkartinė dozė)
English: HIV ANTIVIRAL AGENTS: INTEGRASE STRAND TRANSFER INHIBITORS
Lithuanian: VAISTINIAI PREPARATAI NUO ŽIV INFEKCIJOS: INTEGRAZĖS GRANDINĖS PERNEŠIMO INHIBITORIAI
English: ↔ Naloxone AUC 0.88 (0.76, 1.02) Cmax 0.85 (0.66, 1.09)
Lithuanian: ↔ naloksono AUC 0,88 (0,76; 1,02) Cmax 0,85 (0,66, 1,09)
English: ↔ Tenofovir AUC 1.27 (1.20, 1.35) Cmax 1.14 (0.95, 1.36) C24 1.23 (1.09, 1.40)
Lithuanian: ↔ tenofoviro AUC 1,27 (1,20; 1,35) Cmax 1,14 (0,95; 1,36) C24 1,23 (1,09; 1,40)
English: ↔ Tenofovir AUC 1.18 (1.09, 1.28) Cmax 1.14 (1.04, 1.25) C24 1.24 (1.10, 1.39)
Lithuanian: ↔ tenofoviro AUC 1,18 (1,09; 1,28) Cmax 1,14 (1,04; 1,25) C24 1,24 (1,10; 1,39)
English: ↔ Darunavir AUC 1.11 (0.99, 1.24) Cmax 1.10 (0.96, 1.25) C12 1.00 (0.85, 1.18)
Lithuanian: ↔ darunaviro AUC 1,11 (0,99; 1,24) Cmax 1,10 (0,96; 1,25) C12 1,00 (0,85; 1,18)
English: ↔ Tenofovir AUC 1.18 (1.13, 1.24) Cmax 1.25 (1.14, 1.37) C24 1.20 (1.15, 1.26)
Lithuanian: ↔ tenofoviro AUC 1,18 (1,13; 1,24) Cmax 1,25 (1,14; 1,37) C24 1,20 (1,15; 1,26)
English: Less than 1 % of subjects treated with ZEPATIER with or without ribavirin had serious adverse reactions (abdominal pain, transient ischaemic attack and anaemia).
Lithuanian: Sunkių nepageidaujamų reakcijų (pilvo skausmas, trumpalaikis išemijos priepuolis, anemija) pasireiškė mažiau kaip 1 % ZEPATIER kartu su ribavirinu arba be jo vartojusių tiriamųjų.
English: Inner wallet
Lithuanian: Išorinė dėžutė
English: ↔ Pitavastatin AUC 1.11 (0.91, 1.34) Cmax 1.27 (1.07, 1.52)
Lithuanian: ↔ pitavastatino AUC 1,11 (0,91; 1,34) Cmax 1,27 (1,07; 1,52)
English: ↔ S-Methadone AUC 1.09 (0.94, 1.26) Cmax 1.09 (0.95, 1.25) C24 1.20 (0.98, 1.47)
Lithuanian: ↔ S-metadono AUC 1,09 (0,94; 1,26) Cmax 1,09 (0,95; 1,25) C24 1,20 (0,98; 1,47)
English: Grazoprevir is not a P-gp inhibitor based on in vitro data.
Lithuanian: Tyrimų in vitro duomenimis, grazopreviras P gp neslopina.
English: Buprenorphine/naloxone (8 mg/2 mg single dose)/ elbasvir (50 mg single dose)
Lithuanian: Buprenorfinas / naloksonas Buprenorfinas / naloksonas (8 mg/2 mg vienkartinė dozė) / elbasviras (50 mg vienkartinė dozė)
English: GT 1, 4, 6 TN with or without cirrhosis HCV/HIV-1 co-infection
Lithuanian: GT 1, 4, 6 TN su ciroze arba be jos HCV ir ŽIV-1 infekcijos kartu
English: Montelukast (10 mg single dose)/ grazoprevir (200 mg single dose)
Lithuanian: Montelukastas (10 mg vienkartinė dozė) / grazopreviras (200 mg vienkartinė dozė)
English: • If it has been more than 16 hours since you should have taken your dose, do not take the missed dose.
Lithuanian: • jeigu po laiko vartoti praleistą dozę praėjo daugiau kaip 16 val., tai praleiskite ją, palaukite ir gerkite kitą dozę įprastu laiku;
English: HCV ANTIVIRAL AGENTS
Lithuanian: VAISTINIAI PREPARATAI NUO HCV INFEKCIJOS
English: ↔ Elbasvir AUC 1.17 (1.11, 1.24) Cmax 1.25 (1.16, 1.35) C24 1.04 (0.97, 1.12)
Lithuanian: ↔ elbasviro AUC 1,17 (1,11; 1,24) Cmax 1,25 (1,16; 1,35) C24 1,04 (0,97; 1,12)
English: ↔ Dolutegravir AUC 1.16 (1.00, 1.34) Cmax 1.22 (1.05, 1.40) C24 1.14 (0.95, 1.36)
Lithuanian: ↔ dolutegraviro AUC 1,16 (1,00; 1,34) Cmax 1,22 (1,05; 1,40) C24 1,14 (0,95; 1,36)
English: These changes are not clinically relevant; therefore, no dose adjustment of elbasvir/grazoprevir is recommended based on sex (see section 4.4).
Lithuanian: Šie skirtumai klinikinės reikšmės neturi, todėl koreguoti sudėtinio elbasviro ir grazopreviro preparato dozės dėl lyties nerekomenduojama (žr. 4.4 skyrių).
English: AUC 1.10 (1.05, 1.14) Cmax 1.05 (0.98, 1.12)
Lithuanian: ↔ etinilestradiolio AUC 1,10 (1,05; 1,14) Cmax 1,05 (0,98; 1,12)
English: The dose of atorvastatin should not exceed a daily dose of 20 mg when co-administered with ZEPATIER.
Lithuanian: Kartu su ZEPATIER vartojamo atorvastatino paros dozė turi neviršyti 20 mg.
English: ↔ Buprenorphine AUC 0.98 (0.89, 1.08) Cmax 0.94 (0.82, 1.08) C24 0.98 (0.88, 1.09)
Lithuanian: ↔ buprenorfino AUC 0,98 (0,89; 1,08) Cmax 0,94 (0,82; 1,08) C24 0,98 (0,88; 1,09)
English: ANTIMYCOBACTERIALS
Lithuanian: VAISTINIAI PREPARATAI NUO MIKOBAKTERIJŲ
English: ↔ Grazoprevir AUC 1.16 (0.94, 1.44) Cmax 1.13 (0.77, 1.65) C24 0.93 (0.84, 1.03)
Lithuanian: ↔ grazopreviro AUC 1,16 (0,94; 1,44) Cmax 1,13 (0,77; 1,65) C24 0,93 (0,84; 1,03)
English: ↔ Midazolam AUC 1.34 (1.29, 1.39) Cmax 1.15 (1.01, 1.31)
Lithuanian: ↔ midazolamo AUC 1,34 (1,29; 1,39) Cmax 1,15 (1,01; 1,31)
English: ↔ Rilpivirine AUC 1.13 (1.07, 1.20) Cmax 1.07 (0.97, 1.17) C24 1.16 (1.09, 1.23)
Lithuanian: ↔ rilpivirino AUC 1,13 (1,07; 1,20) Cmax 1,07 (0,97; 1,17) C24 1,16 (1,09; 1,23)
English: • Keep this leaflet.
Lithuanian: • įvertinti Jūsų kepenų funkciją.
English: ↔ R-Methadone AUC 1.03 (0.92, 1.15) Cmax 1.07 (0.95, 1.20) C24 1.10 (0.96, 1.26)
Lithuanian: ↔ R-metadono AUC 1,03 (0,92; 1,15) Cmax 1,07 (0,95; 1,20) C24 1,10 (0,96; 1,26)
English: Proton pump inhibitors Pantoprazole (40 mg once daily)/ elbasvir (50 mg single dose)/ grazoprevir (100 mg single dose)
Lithuanian: Protonų siurblio inhibitoriai Pantoprazolas (40 mg 1 kartą per parą) / elbasviras (50 mg vienkartinė dozė) / grazopreviras (100 mg vienkartinė dozė)
English: ↔ LNG
Lithuanian: TE (angl.
English: AUC 1.01 (0.97, 1.05) Cmax 1.10 (1.05, 1.16)
Lithuanian: ↔ etinilestradiolio AUC 1,01 (0,97; 1,05) Cmax 1,10 (1,05; 1,16)
English: ↔ Grazoprevir AUC 1.10 (0.95, 1.28) Cmax 0.89 (0.71, 1.11) C24 1.12 (0.97, 1.30)
Lithuanian: ↔ grazopreviro AUC 1,10 (0,95; 1,28) Cmax 0,89 (0,71; 1,11) C24 1,12 (0,97; 1,30)
English: ↔ Prednisolone AUC 1.08 (1.01, 1.16) Cmax 1.04 (0.99, 1.09)
Lithuanian: ↔ prednizolono AUC 1,08 (1,01; 1,16) Cmax 1,04 (0,99; 1,09)
English: Ketoconazole (400 mg PO once daily)/ elbasvir (50 mg single dose)
Lithuanian: Ketokonazolas Ketokonazolas (400 mg per burną 1 kartą per parą) / elbasviras (50 mg vienkartinė dozė)
English: Efavirenz (600 mg once daily)/ elbasvir (50 mg once daily)
Lithuanian: Efavirenzas (600 mg 1 kartą per parą) / elbasviras (50 mg 1 kartą per parą)
English: ↑ Grazoprevir AUC 7.50 (5.92, 9.51) Cmax 5.27 (4.04, 6.86) C24 8.05 (6.33, 10.24)
Lithuanian: AUC 7,50 (5,92; 9,51) Cmax 5,27 (4,04; 6,86) C24 8,05 (6,33; 10,24) (OATP1B ir CYP3A slopinimas)
English: Do not chew, crush or split the tablet.
Lithuanian: Nurykite tabletę nepažeistą valgant arba kitu laiku. Jos negalima kramtyti, traiškyti ar laužyti.
English: Raltegravir (400 mg single dose)/ elbasvir (50 mg single dose)
Lithuanian: Raltegraviras Raltegraviras (400 mg vienkartinė dozė) / elbasviras (50 mg vienkartinė dozė)
English: GT 1, 4, 6 TE with or without cirrhosis, and with or without HCV/HIV-1 co-infection
Lithuanian: GT 1, 4, 6 TE su ciroze arba be jos, kartu infekuoti arba neinfekuoti HCV ir ŽIV-1
English: HERBAL SUPPLEMENTS
Lithuanian: VAISTAŽOLINIAI PAPILDAI
English: ↑ Atorvastatin AUC 3.00 (2.42, 3.72) Cmax 5.66 (3.39, 9.45)
Lithuanian: ↑ atorvastatino AUC 3,00 (2,42; 3,72) Cmax 5,66 (3,39; 9,45)
English: ↔ Emtricitabine AUC 1.07 (1.03, 1.10) Cmax 0.96 (0.90, 1.02) C24 1.19 (1.13, 1.25)
Lithuanian: ↔ emtricitabino AUC 1,07 (1,03; 1,10) Cmax 0,96 (0,90; 1,02) C24 1,19 (1,13; 1,25)
English: ↔ Atazanavir AUC 1.07 (0.98, 1.17) Cmax 1.02 (0.96, 1.08) C24 1.15 (1.02, 1.29)
Lithuanian: ↔ atazanaviro AUC 1,07 (0,98; 1,17) Cmax 1,02 (0,96; 1,08) C24 1,15 (1,02; 1,29)
English: If you are on a low sodium diet, talk to your doctor before taking this medicine.
Lithuanian: ZEPATIER sudėtyje yra natrio. Jeigu ribojamas natrio kiekis Jūsų maiste, apie tai pasakykite gydytojui, prieš pradėdami vartoti šį vaistą.
English: ↔ Lopinavir AUC 1.03 (0.96, 1.16) Cmax 0.97 (0.88, 1.08) C12 0.97 (0.81, 1.15)
Lithuanian: ↔ lopinaviro AUC 1,03 (0,96; 1,16) Cmax 0,97 (0,88; 1,08) C12 0,97 (0,81; 1,15)
English: • EBR* + GZR* for 12 weeks (N=14)
Lithuanian: • EBR* + GZR* 12 savaičių (N=14)
English: Most late ALT elevations resolved with ongoing therapy with ZEPATIER or after completion of therapy (see section 4.4).
Lithuanian: Vėlyvieji ALT aktyvumo padidėjimai dažniausiai simptomų nesukeldavo ir normalizuodavosi ZEPATIER vartojant toliau arba baigus numatytą gydymo kursą (žr.
English: ↔ Elbasvir AUC 1.09 (0.98, 1.21) Cmax 1.11 (0.99, 1.26) C24 0.96 (0.86, 1.08)
Lithuanian: ↔ elbasviro AUC 1,09 (0,98; 1,21) Cmax 1,11 (0,99; 1,26) C24 0,96 (0,86; 1,08)
English: ↔ Lopinavir AUC 1.02 (0.93, 1.13) Cmax 1.02 (0.92, 1.13) C12 1.07 (0.97, 1.18)
Lithuanian: ↔ lopinaviro AUC 1,02 (0,93; 1,13) Cmax 1,02 (0,92; 1,13) C12 1,07 (0,97; 1,18)
English: (intestinal BCRP inhibition)
Lithuanian: (žarnų BCRP slopinimas)
English: Sevelamer carbonate (2,400 mg single dose)/ elbasvir (50 mg single dose)/ grazoprevir (100 mg single dose)
Lithuanian: Sevelamero karbonatas (2400 mg vienkartinė dozė) / elbasviras (50 mg vienkartinė dozė) / grazopreviras (100 mg vienkartinė dozė)
English: NS5A polymorphisms (conferring > 5-fold potency loss to elbasvir) included M28T/A, Q30E/H/R/G/K/D, L31M/V/F, H58D, and Y93C/H/N
Lithuanian: NS5A polimorfizmai, sumažinantys elbasviro aktyvumą daugiau kaip 5 kartus, buvo M28T/A, Q30E/H/R/G/K/D, L31M/V/F, H58D ir Y93C/H/N.
English: ↔ Elbasvir AUC 0.97 (0.90, 1.06) Cmax 0.99 (0.88, 1.10) C24 0.92 (0.83, 1.02)
Lithuanian: ↔ elbasviro AUC 0,97 (0,90; 1,06) Cmax 0,99 (0,88; 1,10) C24 0,92 (0,83; 1,02)
English: GT 1, 3 TN with or without cirrhosis TE Null Responder with or without cirrhosis TN HCV/HIV1 co-infection without cirrhosis
Lithuanian: GT 1, 3 TN su ciroze arba be jos TE, kuriems atsako nepasireiškė (su ciroze arba be jos) TN, kartu infekuoti HCV ir ŽIV-1 (be cirozės)
English: ↔ Elbasvir AUC 1.22 (0.98, 1.52) Cmax 1.13 (0.87, 1.46) C24 1.22 (0.99, 1.51)
Lithuanian: ↔ elbasviro AUC 1,22 (0,98; 1,52) Cmax 1,13 (0,87; 1,46) C24 1,22 (0,99; 1,51)
English: • have any other medical conditions.
Lithuanian: • sergate kokia nors kita liga.
English: Based on pooled data from patients treated with ZEPATIER for 12 weeks without ribavirin ULN: Upper limit of normal according to testing laboratory.
Lithuanian: Remiantis pacientų, vartojusių ZEPATIER be ribavirino 12 savaičių, apibendrintais duomenimis.
English: Overall prevalence of GT1b-infected subjects with baseline NS5A polymorphisms in the pooled analyses was
Lithuanian: Atliekant bendras analizes, GT1b infekuoti tiriamieji, iš pradžių turėję NS5A polimorfizmų, sudarė 14 %
English: ↔ Grazoprevir AUC 0.81 (0.67, 0.97) Cmax 0.64 (0.44, 0.93) C24 0.86 (0.79, 0.93)
Lithuanian: ↔ grazopreviro AUC 0,81 (0,67; 0,97) Cmax 0,64 (0,44; 0,93) C24 0,86 (0,79; 0,93)
English: ↔ Montelukast AUC 1.11 (1.01, 1.20) Cmax 0.92 (0.81, 1.06) C24 1.39 (1.25, 1.56)
Lithuanian: ↔ montelukasto AUC 1,11 (1,01; 1,20) Cmax 0,92 (0,81; 1,06) C24 1,39 (1,25; 1,56)
English: Lopinavir/ritonavir (400 mg twice daily)/ ritonavir (100 mg twice daily/ elbasvir (50 mg once daily)
Lithuanian: Lopinaviras / ritonaviras Lopinaviras (400 mg 2 kartus per parą) / ritonaviras (100 mg 2 kartus per parą / elbasviras (50 mg 1 kartą per parą)
English: ↔ Grazoprevir AUC 0.80 (0.53, 1.22) Cmax 0.76 (0.40, 1.44) C24 0.69 (0.54, 0.88)
Lithuanian: ↔ grazopreviro AUC 0,80 (0,53; 1,22) Cmax 0,76 (0,40; 1,44) C24 0,69 (0,54; 0,88)
English: ↔ Elbasvir AUC 1.13 (0.94, 1.37) Cmax 1.07 (0.88, 1.29) C24 1.22 (1.02, 1.45)
Lithuanian: ↔ elbasviro AUC 1,13 (0,94; 1,37) Cmax 1,07 (0,88; 1,29) C24 1,22 (1,02; 1,45)
English: Darunavir/ritonavir (600 mg twice daily)/ ritonavir (100 mg twice daily/ elbasvir (50 mg once daily)
Lithuanian: Darunaviras / ritonaviras Darunaviras (600 mg 2 kartus per parą) / ritonaviras (100 mg 2 kartus per parą / elbasviras (50 mg 1 kartą per parą)
English: ↔ Mycophenolic acid AUC 0.95 (0.87, 1.03) Cmax 0.85 (0.67, 1.07)
Lithuanian: ↔ mikofenolio rūgšties AUC 0,95 (0,87; 1,03) Cmax 0,85 (0,67; 1,07)
English: Placebo-controlled study in which subjects were randomised in a 2:1 ratio to EBR/GZR for 12 weeks (ITG) or placebo for 12 weeks followed by open-label treatment with EBR/GZR for 12 weeks (DTG).
Lithuanian: Tiriamieji randomizuoti santykiu 2:1 vartoti EBR/GZR 12 savaičių (neatidėto gydymo grupė) arba pirmas 12 savaičių placebą ir paskui 12 savaičių EBR/GZR atviru būdu (atidėto gydymo grupė).
English: ASTHMA AGENTS
Lithuanian: VAISTINIAI PREPARATAI NUO ASTMOS
English: ↔ Grazoprevir AUC 0.86 (0.55, 1.12) Cmax 0.78 (0.51, 1.18) C24 0.89 (0.78, 1.01)
Lithuanian: ↔ grazopreviro AUC 0,86 (0,55; 1,12) Cmax 0,78 (0,51; 1,18) C24 0,89 (0,78; 1,01)
English: ↔ Elbasvir AUC 0.92 (0.75, 1.14) Cmax 0.86 (0.71, 1.04) C24 0.87 (0.70, 1.09)
Lithuanian: ↔ elbasviro AUC 0,92 (0,75; 1,14) Cmax 0,86 (0,71; 1,04) C24 0,87 (0,70; 1,09)
English: HCV replicons with reduced susceptibility to elbasvir and grazoprevir have been selected in cell culture for genotypes 1a, 1b and 4.
Lithuanian: Ląstelių kultūroje buvo atrinkti 1a, 1b ir 4 genotipų HCV replikonai, turintys sumažėjusį jautrumą elbasvirui ir grazoprevirui.
English: ↔ Elbasvir AUC 0.81 (0.57, 1.17) Cmax 0.89 (0.61, 1.29) C24 0.80 (0.55, 1.16)
Lithuanian: ↔ elbasviro AUC 0,81 (0,57; 1,17) Cmax 0,89 (0,61; 1,29) C24 0,80 (0,55; 1,16)
English: Following administration of elbasvir/grazoprevir to HCV-infected subjects, elbasvir peak plasma concentrations occur at a median Tmax of 3 hours (range of 3 to 6 hours); grazoprevir peak plasma concentrations occur at a median Tmax of 2 hours (range of 30 minutes to 3 hours).
Lithuanian: HCV infekuotiems žmonėms pavartojus sudėtinio elbasviro ir grazopreviro preparato, didžiausios elbasviro koncentracijos plazmoje susidarymo laiko mediana (Tmax) yra 3 val.
English: ↔ Grazoprevir AUC 0.93 (0.75, 1.17) Cmax 1.16 (0.82, 1.65) C24 0.10 (0.07, 0.13)
Lithuanian: ↔ grazopreviro AUC 0,93 (0,75; 1,17) Cmax 1,16 (0,82; 1,65) C24 0,10 (0,07; 0,13)
English: ↔ Elbasvir AUC 1.05 (0.93, 1.18) Cmax 1.02 (0.92, 1.14) C24 1.03 (0.92, 1.17)
Lithuanian: ↔ elbasviro AUC 1,05 (0,93; 1,18) Cmax 1,02 (0,92; 1,14) C24 1,03 (0,92; 1,17)
English: The dose of rosuvastatin should not exceed a daily dose of 10 mg when co-administered with ZEPATIER.
Lithuanian: Kartu su ZEPATIER vartojamo rozuvastatino paros dozė turi neviršyti 10 mg.
English: Tenofovir disoproxil fumarate (300 mg once daily)/ elbasvir (50 mg once daily)
Lithuanian: Tenofoviro disoproksilio fumaratas Tenofoviro disoproksilio fumaratas (300 mg 1 kartą per parą) / elbasviras (50 mg 1 kartą per parą)
English: ↔ Grazoprevir AUC 0.79 (0.68, 0.91) Cmax 0.57 (0.40, 0.83) C24 0.77 (0.61, 0.99)
Lithuanian: ↔ grazopreviro AUC 0,79 (0,68; 0,91) Cmax 0,57 (0,40; 0,83) C24 0,77 (0,61; 0,99)
English: ↔ Elbasvir AUC 1.05 (0.92, 1.18) Cmax 1.11 (0.98, 1.26) C24 1.03 (0.91, 1.17)
Lithuanian: ↔ elbasviro AUC 1,05 (0,92; 1,18) Cmax 1,11 (0,98; 1,26) C24 1,03 (0,91; 1,17)
English: Based on pooled data from patients treated with ZEPATIER for 12 weeks without ribavirin
Lithuanian: Dažnas astenija, irzlumas * Remiantis pacientų, vartojusių ZEPATIER 12 savaičių be ribavirino, apibendrintais duomenimis.
English: Based on the population pharmacokinetic modeling in non-cirrhotic, HCV-infected subjects, the geometric mean steady-state elbasvir AUC0-24 and Cmax at 50 mg were 2,180 nM•hr and 137 nM, respectively, and the geometric mean steady-state grazoprevir AUC0-24 and Cmax at 100 mg were 1,860 nM•hr and 220 nM, respectively.
Lithuanian: Remiantis farmakokinetikos ciroze nesergančių HCV infekuotų žmonių organizme populiaciniu modeliavimu, vartojant elbasviro 50 mg dozę, susidarius pusiausvyros koncentracijai jo AUC0-24 geometrinis vidurkis buvo 2 180 nM×val.
English: ↔ EE
Lithuanian: A.
English: ↔ Grazoprevir AUC 0.89 (0.72, 1.09) Cmax 0.85 (0.62, 1.16) C24 0.90 (0.82, 0.99)
Lithuanian: ↔ grazopreviro AUC 0,89 (0,72; 1,09) Cmax 0,85 (0,62; 1,16) C24 0,90 (0,82; 0,99)
English: AUC 1.23 (1.15, 1.32) Cmax 0.93 (0.84, 1.03)
Lithuanian: ↔ levonorgestrelio AUC 1,23 (1,15; 1,32) Cmax 0,93 (0,84; 1,03)
English: ↔ Grazoprevir AUC 1.09 (0.95, 1.25) Cmax 1.34 (1.10, 1.62) C24 0.93 (0.87, 1.00)
Lithuanian: ↔ grazopreviro AUC 1,09 (0,95; 1,25) Cmax 1,34 (1,10; 1,62) C24 0,93 (0,87; 1,00)
English: (P-gp inhibition)
Lithuanian: (P gp slopinimas)
English: ↔ Grazoprevir AUC 0.98 (0.89, 1.07) Cmax 0.97 (0.83, 1.14) C24 1.00 (0.93, 1.07)
Lithuanian: ↔ grazopreviro AUC 0,98 (0,89; 1,07) Cmax 0,97 (0,83; 1,14) C24 1,00 (0,93; 1,07)
English: ↔ Grazoprevir AUC 0.81 (0.70, 0.95) Cmax 0.72 (0.57, 0.92) C24 0.91 (0.82, 1.01)
Lithuanian: ↔ grazopreviro AUC 0,81 (0,70; 0,95) Cmax 0,72 (0,57; 0,92) C24 0,91 (0,82; 1,01)
English: ↑ Grazoprevir AUC 10.58 (7.78, 14.39) Cmax 6.24 (4.42, 8.81) C24 11.64 (7.96, 17.02)
Lithuanian: AUC 10,58 (7,78; 14,39) Cmax 6,24 (4,42; 8,81) C24 11,64 (7,96; 17,02) (OATP1B ir CYP3A slopinimas)
English: Rifampicin (600 mg IV single dose)/ elbasvir (50 mg single dose)
Lithuanian: Rifampicinas Rifampicinas (600 mg į veną vienkartinė dozė) / elbasviras (50 mg vienkartinė dozė)
English: ↔ Grazoprevir AUC 0.74 (0.60, 0.92) Cmax 0.58 (0.42, 0.82) C24 0.97 (0.89, 1.06)
Lithuanian: ↔ grazopreviro AUC 0,74 (0,60; 0,92) Cmax 0,58 (0,42; 0,82) C24 0,97 (0,89; 1,06)
English: ↔ Elbasvir AUC 1.17 (0.98, 1.39) Cmax 1.29 (1.06, 1.58) C24 1.21 (1.03, 1.43)
Lithuanian: ↔ elbasviro AUC 1,17 (0,98; 1,39) Cmax 1,29 (1,06; 1,58) C24 1,21 (1,03; 1,43)
English: Co-administration with ZEPATIER is contraindicated.
Lithuanian: Kartu su ZEPATIER vartoti negalima.
English: Table 9: SVR in genotype 1b †-infected subjects Baseline Characteristics
Lithuanian: SVA 1b † genotipo virusais infekuotiems tiriamiesiems Pradiniai duomenys
English: ↔ Grazoprevir AUC 1.01 (0.79, 1.28) Cmax 0.97 (0.63, 1.50) C24 0.95 (0.87, 1.04)
Lithuanian: ↔ grazopreviro AUC 1,01 (0,79; 1,28) Cmax 0,97 (0,63; 1,50) C24 0,95 (0,87; 1,04)
English: Among genotype 1b/1 other-infected subjects, the median age was 55 years (range: 22 to 82); 61% were male; 60 % were White; 20% were Black or African American; 6% were Hispanic or Latino; 82% were treatment-naïve subjects; 18% were treatment-experienced subjects; mean body mass index was 26 kg/m2; 64 % had baseline HCV RNA levels greater than 800,000 IU/mL; 22 % had cirrhosis; 71% had non-C/C IL28B alleles (CT or TT); 18 % had HCV/HIV-1 co-infection.
Lithuanian: 1b ar kitokio 1 genotipo virusų infekuotų tiriamųjų amžiaus mediana buvo 55 metai (diapazonas - nuo 22 iki 82), 61 % buvo vyrai, 60 % baltieji, 20 % juodaodžiai arba afroamerikiečiai, 6 % kilę iš ispaniškai kalbančių arba Lotynų Amerikos šalių, 82 % anksčiau negydyti, 18 % anksčiau gydyti.
English: If you take more ZEPATIER than you should, talk to a doctor straight away.
Lithuanian: Ką daryti pavartojus per didelę ZEPATIER dozę? Pavartoję per didelę ZEPATIER dozę, apie tai tuoj pat pasakykite gydytojui.
English: ↔ Grazoprevir AUC 1.12 (0.96, 1.30) Cmax 1.10 (0.89, 1.37) C24 1.17 (1.02, 1.34)
Lithuanian: ↔ grazopreviro AUC 1,12 (0,96; 1,30) Cmax 1,10 (0,89; 1,37) C24 1,17 (1,02; 1,34)
English: ↔ Elbasvir AUC 0.93 (0.82, 1.05) Cmax 0.88 (0.77, 1.00) C24 0.92 (0.18, 1.05)
Lithuanian: ↔ elbasviro AUC 0,93 (0,82; 1,05) Cmax 0,88 (0,77; 1,00) C24 0,92 (0,18; 1,05)
English: ↔ Ciclosporin AUC 0.96 (0.90, 1.02) Cmax 0.90 (0.85, 0.97) C12 1.00 (0.92, 1.08)
Lithuanian: ↔ ciklosporino AUC 0,96 (0,90; 1,02) Cmax 0,90 (0,85; 0,97) C12 1,00 (0,92; 1,08)
English: Subjects with baseline NS5A polymorphisms, % (n/N)
Lithuanian: Tiriamieji su pradiniais NS5A polimorfizmais, % (n/N)
English: ↔ Elbasvir AUC 1.07 (1.00, 1.14) Cmax 1.07 (0.98, 1.16) C24 1.05 (0.97, 1.14)
Lithuanian: ↔ elbasviro AUC 1,07 (1,00; 1,14) Cmax 1,07 (0,98; 1,16) C24 1,05 (0,97; 1,14)
English: Placebo-controlled study in subjects with CKD Stage 4 (eGFR 15-29 mL/min/1.73 m2) or Stage 5 (eGFR < 15 mL/min/1.73 m2), including subjects on hemodialysis, Subjects were randomised in a 1:1 ratio to one of the following treatment groups: EBR + GZR for 12 weeks (ITG) or placebo for 12 weeks followed by open-label treatment with EBR/GZR for 12 weeks (DTG).
Lithuanian: Tiriamieji sirgo 4 stadijos (aGFG 15-29 ml/min/1,73 m2) arba 5 stadijos (aGFG < 15 ml/min/1,73 m įskaitant hemodializuojamus) lėtine inkstų liga.
English: Midazolam (2 mg single dose)/ grazoprevir (200 mg once daily)
Lithuanian: Midazolamas (2 mg vienkartinė dozė) / grazopreviras (200 mg 1 kartą per parą)
English: ↔ Efavirenz AUC 1.00 (0.96, 1.05) Cmax 1.03 (0.99, 1.08) C24 0.93 (0.88, 0.98)
Lithuanian: ↔ efavirenzo AUC 1,00 (0,96; 1,05) Cmax 1,03 (0,99; 1,08) C24 0,93 (0,88; 0,98)
English: (combination of OATP1B and CYP3A inhibition)
Lithuanian: (OATP1B ir CYP3A slopinimas)
English: ↔ Grazoprevir AUC 1.12 (0.97, 1.30) Cmax 1.07 (0.83, 1.37) C24 0.94 (0.87, 1.02)
Lithuanian: ↔ grazopreviro AUC 1,12 (0,97; 1,30) Cmax 1,07 (0,83; 1,37) C24 0,94 (0,87; 1,02)
English: Co-administration of ZEPATIER with strong CYP3A inhibitors increases elbasvir and grazoprevir plasma concentrations, and co-administration is not recommended (see Table 2 and section 4.4).
Lithuanian: Kartu su ZEPATIER vartojant stiprių CYP3A inhibitorių, padidėja elbasviro ir grazopreviro koncentracijos plazmoje, todėl tokie deriniai nerekomenduojami (žr.
English: Overall prevalence of GT1a-infected subjects with baseline NS5A polymorphisms in the pooled analyses was
Lithuanian: Atliekant bendras analizes, GT1a infekuoti tiriamieji, iš pradžių turėję NS5A polimorfizmų, sudarė 7 %
English: Pitavastatin (1 mg single dose)/ grazoprevir (200 mg once daily)
Lithuanian: Pitavastatinas (1 mg vienkartinė dozė) / grazopreviras (200 mg 1 kartą per parą)
English: ↔ Elbasvir AUC 1.07 (1.00, 1.15) Cmax 1.07 (0.99, 1.16) C24 1.04 (0.98, 1.11)
Lithuanian: ↔ elbasviro AUC 1,07 (1,00; 1,15) Cmax 1,07 (0,99; 1,16) C24 1,04 (0,98; 1,11)
English: Atorvastatin (20 mg single dose)/ grazoprevir (200 mg once daily)
Lithuanian: Atorvastatinas Atorvastatinas (20 mg vienkartinė dozė) / grazopreviras (200 mg 1 kartą per parą)
English: ↔ Elbasvir AUC 0.98 (0.93, 1.04) Cmax 0.97 (0.89, 1.05) C24 0.98 (0.93, 1.03)
Lithuanian: ↔ elbasviro AUC 0,98 (0,93; 1,04) Cmax 0,97 (0,89; 1,05) C24 0,98 (0,93; 1,03)